The Lancet17h
The era of GLP-1 receptor agonists: costs versus benefits
Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...
Ro, Lilly partnership creates volatility for Hims & Hers shares, says Leerink
The partnership between Ro and Eli Lilly (LLY) to streamline access to Lilly’s GLP-1 Zepbound single-dose vials for Ro patients with obesity is ...
Medscape1d
CGM Use, GLP-1s, Drinking Water Key of 2025 ADA Standards
The new guidance includes updates on diabetes technology use, GLP-1 receptor agonists, liver disease, drinking water, and ...
Daily2d
American Diabetes Association Unveils Standards of Care in Diabetes-2025
The American Diabetes Association has released the Standards of Care in Diabetes-2025, the authoritative guide for ...
The American Diabetes Association Releases Standards of Care in Diabetes--2025
Today, the American Diabetes Association® released the Standards of Care in Diabetes—2025 (Standards of Care) the gold ...
Business Insider6d
Hims & Hers Health: Buy Rating Backed by Promising Growth in GLP-1 Market and Strong Telehealth Positioning
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Maria Ripps has given her Buy rating due to a combination of factors including the promising growth prospects ...